Federal Trade Commission sues AbbVie, Teva in "pay for delay" deal

The Federal Trade Commission filed a complaint Monday against AbbVie and Teva Pharmaceutical Industries alleging the companies illegally blocked American consumers’ access to lower-cost versions of the testosterone replacement therapy AndroGel. According to the FTC complaint, AbbVie (NYSE: ABBV) of Chicago and its partner Besins Healthcare Inc. allegedly filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of AndroGel,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: research